Logo
x

Search

Subscribe Now

Zura Bio

Zura Bio Reports Global P-II (TibuSURE) Trial of Tibulizumab to Treat Adults with Systemic Sclerosis

Zura Bio Reports Global P-II (TibuSURE) Trial of Tibulizumab to Treat Adults with Systemic Sclerosis

  • December 26, 2024
Zura Bio Reports $80M Financing and Licensing of ZB-106 from Eli Lilly for Autoimmune Diseases 

Zura Bio Reports $80M Financing and Licensing of ZB-106 from Eli Lilly for Autoimmune Diseases 

  • April 28, 2023
Zura Bio to Go Public via JATT SPAC Merger for ~$215M

Zura Bio to Go Public via JATT SPAC Merger for ~$215M

  • June 20, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.